Gennex Laboratories Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Gennex Laboratories Ltd. on BSE

Search Inside the pdf :

Gennex Laboratories Ltd.

04 Jun 2025

12.41

1.55%

Corp. Note

Gennex Laboratories Ltd - 531739 - Board Meeting Outcome for Outcome Of The Board Meeting Of …

BSE India

Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015 ('Listing Regulations') read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we wish to inform you that Board of Directors of the Company, at its meeting held today, on June 04, 2025 has considered and approved the following: 1. Allotment of 40,00,000 Equity Shares upon Conversion of Warrants to the member of promoter group on Preferential basis The requisite disclosures are set out in Annexure A to this letter. We hereby submit that the Board Meeting had commenced at 02:00 PM and concluded at 02.30 PM. This intimation is also uploaded on the Company website: www.gennexlab.com We request you to take the above information on record and acknowledge the receipt of the same.

pdf

Gennex Laboratories Ltd.

02 Jun 2025

12.41

1.55%

Company Update

Gennex Laboratories Ltd - 531739 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Pursuant to Regulation 47 of SEBI (LODR), 2015, please find enclosed herewith Newspaper publication on Audited (Standalone and Consolidated) Financial Results for the Quarter and Year ended March 31, 2025 announced by the Board of Directors in its meeting held on Friday May 30, 2025. Financial results had been published in both Business Standard (English) and Saksham (Telugu - Local) on June 01/02, 2025. We request you to take above information on record and acknowledge receipt of the same.

pdf

Gennex Laboratories Ltd.

30 May 2025

12.41

1.55%

Company Update

Gennex Laboratories Ltd - 531739 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

In compliance with Regulation 24A of SEBI (LODR) Regulations 2015, Board appointment M/s. Mohammed Tausif Shamim & Co., Practicing Company Secretary, Kolkata as Secretarial Auditor of the Company for the Financial Year ended 31.03.2025. They carried out the Secretarial Audit and submitted the Annual Secretarial Compliance Report with reference to the SEBI Circular CIF/CFD/CMPI/27/2019 dated 09.02.2019. We hereby submit the Annual Secretarial Compliance Report issued by the Secretarial Auditor within the timeline allowed by SEBI Circular vide No.SEBI/HO/CFD/CMD1/P/CIR/2021/556, dated 29.04.2021. We request you to take the above information on record and acknowledge the receipt of the same.

pdf

Gennex Laboratories Ltd.

30 May 2025

12.41

1.55%

Company Update

Gennex Laboratories Ltd - 531739 - Appointment Of Mr. Sandeep Kumar Daga As Additional (Non-Executive Non …

BSE India

Pursuant to Regulation 30 read with Part A of Schedule III of SEBI (LODR) Regulations 2015 ("Listing Regulations" we would like to inform you that based on the recommendation of the Nomination & Remuneration Committee the Board of Directors of the Company approved the appointment of Mr. Sandeep Kumar Daga (DIN 00860908) as an Additional (Non-Executive Non-Independent) Director of the Company with effect from 30.05.2025 subject to the approval of Shareholders of the Company. Mr. Snadeep Kumar Daga will be a Non-Executive Non-Independent Director and he is not related to the Promoter or Promoter Group and fulfills the criteria as required under the provisions of the Companies Act, 2013 and the Rules framed thereunder and the Listing Regulations. The relevant details of the captioned appointment as per the requirements of Regulation 30 of SEBI (LODR) Regulations 2015 read with SEBI Circular 2023/123, dated 03.07.2023 are given in the enclosed Annexure-A.

pdf

Gennex Laboratories Ltd.

30 May 2025

12.41

1.55%

Board Meeting

Gennex Laboratories Ltd - 531739 - Board Meeting Outcome for Outcome Of Board Meeting Held On …

BSE India

In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Audited Standalone & Consolidated Financial results for the Quarter & Year Ended March 31, 2025; 2. Auditor''s Report on audited Standalone & Consolidated Financial Statements for the Quarter and Year ended March 31, 2025, issued on dated May 30, 2025 along with the Statement on Impact of Audit Qualification (Standalone & Consolidated) are attached herewith - Annexure I; 3. Appointment of Mr. Sandeep Kumar Daga as Non-Executive Non-Independent Director of the Company; 4. Resignation of Dr. S CH Dharma Rao as Non-Executive Non-Independent Director of the Company; We hereby submit that the Board Meeting had commenced at 4:00 PM and concluded at 6.15 PM. This intimation is also uploaded on the Company website: www.gennexlab.com We request you to take the above information on record and acknowledge the receipt of the same.

pdf

Gennex Laboratories Ltd.

22 May 2025

12.41

1.55%

Company Update

Gennex Laboratories Ltd - 531739 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith Newspaper publication regarding Meeting of Board of Directors of the Company scheduled to be held on Friday, May 30, 2025 for Adoption of Audited (Standalone and Consolidated) Financial Results for the Quarter and Year ended March 31, 2025 along with the Report of the Statutory Auditors thereon. Notice had been published both in Business Standard and Saksham (Local-Telugu) on May 21, 2025. We request you to take the above information on record and acknowledge receipt of the same.

pdf

Gennex Laboratories Ltd.

22 May 2025

12.41

1.55%

Company Update

Gennex Laboratories Ltd - 531739 - Approval Of Additional Products From Drugs Control Administration, Government Of …

BSE India

We are pleased to inform you that our Subsidiary Company, M/s Deccan Remedies Limited, has received Approval from the Drugs Control Administration, Government of Andhra Pradesh granting manufacture of Additional Products under Form 25, valid upto May 28, 2028, for Domestic and Export purpose is enclosed herewith. Approval received from DCA- Government of Andhra Pradesh is enclosed herewith for your information and for taking the same on record.

pdf

Gennex Laboratories Ltd.

20 May 2025, 04:26PM

12.41

1.55%

Board Meeting

Gennex Laboratories Ltd - 531739 - Board Meeting Intimation for For Consideration And Approval Of Audited …

BSE India

Gennex Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve 1. Consider and adopt the Audited Financial Statements (Standalone and Consolidated) for the quarter and year ended March 31, 2025; 2. Consider the Independent Reports'' of the Statutory Auditor on Standalone and Consolidated Financial Statements for the quarter and year ended March 31, 2025; 3. Other Business items. Further, in continuation to earlier disclosure dated March 26, 2025, regarding the closure of trading window w.e.f. April 01, 2025 in pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, Trading Window for dealing in the securities of the Company shall open after 48 hours of declaration of Audited Financial Results for the quarter and year ended March 31, 2025 for all designated persons, their immediate relatives and all connected persons covered under the aforesaid code. This intimation is also being uploaded on the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge receipt of the same.

pdf

Gennex Laboratories Ltd.

22 Apr 2025

12.41

1.55%

Company Update

Gennex Laboratories Ltd - 531739 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

With reference to the captioned subject matter, pursuant to Regulation 74(5) of SEBI (DP) Regulations, 2018, we hereby submit the certificate received from M/s. R&D Infotech Private Limited, Registrar and Transfer Agent of the Company for the quarter ended March 31, 2025. We request you to take the above information on record and acknowledge receipt of the same.

pdf

Gennex Laboratories Ltd.

26 Mar 2025

12.41

1.55%

SAST

Gennex Laboratories Ltd - 531739 - Closure of Trading Window

BSE India

Notice is hereby given that in pursuance of SEBI (PIT) Regulations, 2015 and Company''s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the Trading Window for dealing in the Securities of the Company shall remain closed from April 01, 2025 till 48 hours after the Public announcement through Board of Directors in their Meeting held for announcing the audited Financial Results for the Quarter and Year ended on March 31, 2025 along with other matters for which Trading Window is required to be closed. The Board Meeting date to approve the audited financial results of the Company for the quarter and year ending on March 31, 2025 will be informed in due course. All Promoters/designated/connected persons are advised not to trade in the securities of the Company either directly or indirectly during the aforesaid period of Closure of Trading Window. We request you to take the above information on record and acknowledge receipt of the same.

pdf

Is Gennex Laboratories Ltd. worth buying?

128 Votes:

Buy 83.59%

Sell 6.25%

Hold 10.16%